共 50 条
- [41] Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States JOURNAL OF CROHNS & COLITIS, 2017, 11 : S426 - S426
- [42] Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis JOURNAL OF CROHNS & COLITIS, 2022, 16 (10): : 1562 - 1570
- [45] vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn's disease - a meta-analysis JOURNAL OF CROHNS & COLITIS, 2023, 17 : 694 - 694
- [46] Comparative effectiveness between ustekinumab and vedolizumab after anti-TNF failure in Ulcerative Colitis: Real-world experience JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1186 - i1186
- [47] Biologic Therapy Sequencing in Ulcerative Colitis: A Real-World Observational Study of Second-Line Therapy After Vedolizumab AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S40 - S40
- [48] Systematic Literature Review of Real-World Effectiveness and Safety of Vedolizumab in Adult Ulcerative Colitis and Crohn's Disease Patients AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S298 - S298
- [49] Commentary on the real-world effectiveness of vedolizumab in therapy-experienced ulcerative colitis: A response to Azzam et al. SAUDI JOURNAL OF GASTROENTEROLOGY, 2025, 31 (02): : 100 - 101
- [50] Real-World Treatment Persistence with Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease: A Retrospective Claims Analysis in the US AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S322 - S324